Shots:

• Agenus to receive a $200M as up front & ~$1.36B as development- regulatory and commercial milestones plus royalties on net sales of the therapies. Agenus will retain options to conduct clinical studies and combination studies with other pipeline assets and to co-promote AGEN1777 in the US
• BMS will be solely responsible for the development & commercialization of AGEN1777 and its related products globally
• Agenus expects to file an IND to the US FDA for AGEN1777 in Q2’21. BMS intends to advance the research and development of AGEN1777 in immuno-oncology for tumor indications including NSCLC

  Ref: GLOBE NEWSWIRE | Image: BMS